• About Us
    • Contact Us
    • Login
    • ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
About Us Contact Us Login ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
Grand Rounds

Does Microscopic Inflammation Impact Pregnancy Risks Associated with IBD?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Mårild et al. (EClinicalMedicine, 2022) investigated whether histological inflammation in addition to clinical findings predicts adverse pregnancy outcomes associated with inflammatory bowel disease (IBD)

METHODS:

  • Nationwide cohort study
    • Swedish national registries
  • Population
    • Women diagnosed with IBD and a pre-pregnancy (<12 months) colorectal biopsy with vs without histological inflammation (1990 to 2016)
    • Women with IBD 2007 to 2016 with vs. without clinically active disesase (i.e., IBD-related hospitalization, surgery, or medication escalation) <12 months before pregnancy
  • Exposures
    • With vs without histological inflammation
    • Clinically active IBD vs not clinically active
  • Study design
    • Estimate of risk ratio (RR) performed with adjustment for smoking, socio-demographics, and comorbidities (aRR)
  • Primary outcomes
    • Preterm birth: <37 weeks
    • Small for gestational age (SGA): <10th percentile weight for age

RESULTS:

  • With inflammation: 1223 births | Without inflammation: 630 births
  • There was an increased risk of preterm birth to women with histological inflammation, compared to those without
    • With: 9.6%
    • Without: 6.5%
    • aRR 1.46 (95% CI, 1.03 to 2.06)
  • Histological inflammation was associated with preterm birth in ulcerative colitis but not in Crohn’s disease
    • Ulcerative colitis: aRR 1.64 (95% CI, 1.07 to 2.52)
    • Extensive colitis: aRR 2.37 (95% CI, 1.12 to 5.02)
    • Crohn’s: aRR 0.99 (95% CI, 0.55 to 1.78)
  • There was no significantly increased risk of SGA for women with histological inflammation
    • With: 9.6%
    • Without: 8.9%
    • aRR 1.09 (95% CI, 0.81 to 1.47)
  • Clinically active IBD: 2110 women | Inactive IBD: 4993 births
  • Clinically active disease before pregnancy was linked to preterm birth but not SGA
    • Preterm birth: aRR 1.42 (95% CI, 1.20 to 1.69)
    • SGA: aRR 1.13 (95% CI, 0.96 to 1.32)
  • For infants born to women without clinical activity, inflammation was not associated with preterm birth
    • aRR 1.20 (95% CI, 0.68 to 2.13)

CONCLUSION:

  • Both histological inflammation and clinical activity in IBD increased the risk of preterm birth, especially for ulcerative colitis
  • The authors state

Our data support recommendations to objectively assess endoscopic and histologic disease remission before conception, to optimize management and prevent adverse outcomes of pregnancy and IBD. This is particularly important against the background that in our IBD cohort (1990–2016), two thirds of biopsied women had histological inflammation and one third had clinical disease activity within 12 months before pregnancy

Learn More – Primary Sources:

Histological remission in inflammatory bowel disease and risk of adverse pregnancy outcomes: A nationwide study

Want to stay on top of key guidelines and research papers?

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

Is Greater IBD Severity Associated with Worse Pregnancy Outcomes?
Biologics for Crohn’s Disease: Safety in Pregnancy and Placental Transfer
Meta-Analysis: Is Exposure to Biologics During Pregnancy Linked to Worse Outcomes?

Sections

  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • COVID-19

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site